Furthermore, targeting metabolic pathways of cancer and related cells in the TME contributing to nutrient and metabolic stress has become an area of growing interest with multiple therapeutic targets under consideration, including IDO, MCT1/MCT4, mitochondrial complex I, and the mitochondrial tricarboxylic acid (TCA) cycle (237–240). This evidence concerns the gene IDO1 and cancer.